#BIO2015: What life sciences sectors are ripe for M&A?
(from MedCity News)
In this bullish life sciences market, which sectors are most ripe for acquisition? Which assets will have a tougher time to sell?
A report, released at this week’s BIO International Convention in Philadelphia by management consultancy Campbell Alliance, laid out a number of interesting insights on the M&A environment in the life sciences. Study author Neel Patel discussed the results.
Most notable was the firm’s breakdown of demand by sector. CNS therapies topped the list of most lucrative acquisition targets — the growing Alzheimer’s market is clearly one reason for this. Close behind was pain — not surprising either, given the huge need these days for safer opioids and other abuse-deterrent options.